Scientists have developed a coffee machine-sized 3D bioprinter that produces human-like tissue in a move they hope could potentially speed up the development of new treatments for the likes of heart ...

Carolyn Schutt Ibsen uses ultrasound to improve tumor targetingand tissue engineering from bioink to 3D models.

Worldwide obesity rates have more than doubled since 1990, with nearly a billion people now falling into the category. Though ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

IF YOUR MAIN FITNESS goal is to add mass and chisel out your figure, then the thought of building "lean muscle" likely sounds rather appealing. After all, why would you dedicate hours in the gym ...

Enhanc3D Genomics has announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery. The new 3D multi-omics offerings were designed to ...

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four years later, she and her husband, Ken, halted the treatment.

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. Current ...

Triastek, a 3D pharmaceutical printing company, has reported positive results for its 3D printed drug, D23 (Budesonide Ileum-Targeted Tablets), designed to treat IgA nephropathy (IgAN). D23 is a ...

The team examined the effect of this variant on different types of lean mass, including appendicular ... allows us to gain valuable insights into drug target effects in a timely and cost-efficient ...

The research from Washington University leverages this concept by developing 3D-printed scaffolds that support tissue formation while maintaining electrical conductivity, which could be useful in drug ...

Brian Pacheco New York The writer is the managing director of communications for the Drug Policy Alliance. To the Editor: Nicholas Kristof’s column starts with a faulty and harmful premise ...